GlassScriptPhysician profile
Emily B Johnson
NPI 1629253950
$2,068.22
in general payments reported to CMS, 2019-2025
25 companies · $444 in 2025
The $444 reported for 2025 was more than what 78% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $104 · 2020: $117 · 2021: $656 · 2022: $108 · 2023: $389 · 2024: $250 · 2025: $444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,083.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,083.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $650.47 | 2019-2023 | |
| Intuitive Surgical, INC. | $223.15 | 2025 | |
| Mayne Pharma Commercial LLC | $218.11 | 2021-2025 | |
| Hologic Sales and Service, LLC | $158.90 | 2020-2025 | Novasure, Myosure Tissue Removal Device, Aptima |
| Gynesonics, INC. | $143.53 | 2021 | |
| Astellas Pharma US INC | $132.27 | 2020-2025 | Veozah |
| Organon LLC | $78.80 | 2021-2025 | Nexplanon, Nuvaring |
| Takeda Pharmaceuticals U.S.A., INC. | $76.39 | 2021-2025 | Trintellix |
| Amgen INC. | $48.74 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $46.02 | 2025 | Gemtesa, Myfembree |
| Bayer Healthcare Pharmaceuticals INC. | $31.90 | 2023-2025 | |
| Novo Nordisk INC | $28.54 | 2022-2023 | Saxenda, Wegovy |
| Lilly USA, LLC | $28.41 | 2025 | Zepbound |
| Radius Health, INC. | $25.40 | 2020-2021 | |
| Exeltis, USA INC. | $24.72 | 2024 | Slynd |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $23.02 | 2019 | |
| Conmed Corporation | $21.85 | 2024 | Airseal |
| Shield Therapeutics INC | $18.96 | 2024 | |
| Merck Sharp & Dohme LLC | $17.28 | 2020 | |
| Evofem Biosciences, INC. | $13.15 | 2021 | |
| Daiichi Sankyo INC. | $13.09 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.51 | 2022 | |
| Avanos Medical | $12.42 | 2019 | |
| Vertical Pharmaceuticals, LLC | $10.96 | 2019 | |
| Channel Medsystems, INC. | $9.63 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.